Drugs / MSC Supernatant
MSC Supernatant
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06599346 | Oct 2020 → Sep 2025 overdue | mucositis | The General Hospital of Western Theater Command | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSC Supernatant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06599346 ↗ |
| Known as | Mesenchymal Stem Cell Culture Supernatant | “Study on the Effects of Mesenchymal Stem Cell Culture Supernatant on the Prevention and Treatment of Mucosal Injury in Hematology Patients” NCT06599346 ↗ |
| Known as | Mesenchymal Stem Cell Supernatant | “Effects of Mesenchymal Stem Cell Supernatant on Prevention and Treatment of Skin/Mucosal Injury in Hematology Patients” NCT06599346 ↗ |
| Known as | MSC culture supernatant | “MSC culture supernatant contains substances produced by mesenchymal stem cells that may promote healing and reduce inflammation.” NCT06599346 ↗ |
| Route | Topical | “15 mL for oral mucosal injuries (mouthwash)” NCT06599346 ↗ |